• Vice President, Drug Discovery, Southern Research Institute
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2018 Identification of Cosalane as an Inhibitor of Human and Murine CC–Chemokine Receptor 7 Signaling via a High-Throughput ScreenSlas Discovery.  23:1083-1091. 2018
    2018 Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interactionCancer Letters.  434:11-21. 2018
    2018 Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic diseaseCollagen and related research.  68-69:28-43. 2018
    2018 Retraction notice to “SRI36160 is a specific inhibitor of Wnt/<beta>-catenin signaling in human pancreatic and colorectal cancer cells” [Canc. Lett. 389C (2017) 41–48] (S030438351630800X) (10.1016/j.canlet.2016.12.030))Cancer Letters.  422:131. 2018
    2018 Preferential inhibition of Wnt/β-catenin signaling by novel benzimidazole compounds in triple-negative breast cancerInternational Journal of Molecular Sciences.  19. 2018
    2018 Structure-activity relationships and cellular mechanism of action of small molecules that enhance the delivery of oligonucleotidesNucleic Acids Research.  46:1601-1613. 2018
    2017 Predicting radiotherapy response for patients with soft tissue sarcoma by developing a molecular signatureOncology Reports.  38:2814-2824. 2017
    2017 SRI36160 is a specific inhibitor of Wnt/β-catenin signaling in human pancreatic and colorectal cancer cellsCancer Letters.  389:41-48. 2017
    2017 Retraction of "Design and Synthesis of Novel Cyclic Amine Benzimidazoles for the Treatment of Pancreatic Cancer".Journal of Medicinal Chemistry.  60:7615. 2017
    2017 Development of a radiosensitivity gene signature for patients with soft tissue sarcomaOncotarget.  8:27428-27439. 2017
    2017 Discovery of novel frizzled-7 inhibitors by targeting the receptor's transmembrane domainOncotarget.  8:91459-91470. 2017
    2017 Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunitOncotarget.  8:37568-37583. 2017
    2016 Identification of small molecule inhibitors of human cytochrome c oxidase that target chemoresistant glioma cellsJournal of Biological Chemistry.  291:24188-24199. 2016
    2016 Discovery of clinically approved agents that promote suppression of cystic fibrosis transmembrane conductance regulator nonsense mutationsAmerican Journal of Respiratory and Critical Care Medicine.  194:1092-1103. 2016
    2016 Discovery of a novel inhibitor of kinesin-like protein KIFC1Biochemical Journal.  473:1027-1035. 2016
    2016 Consortia's critical role in developing medical countermeasures for re-emerging viral infections: A USA perspectiveFuture Virology.  11:187-195. 2016
    2016 Inhibition of transforming growth factor-β activation diminishes tumor progression and osteolytic bone disease in mouse models of multiple myelomaAmerican Journal of Pathology.  186:678-690. 2016
    2015 High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotidesNucleic Acids Research.  43:1987-1996. 2015
    2014 Unique functional and structural properties of the LRRK2 protein ATP-binding pocketJournal of Biological Chemistry.  289:32937-32951. 2014
    2014 AlphaScreen HTS and live-cell bioluminescence resonance energy transfer (bret) assays for identification of Tau-Fyn sh3 interaction inhibitors for Alzheimer diseaseJournal of Biomolecular Screening.  19:1338-1349. 2014
    2013 Role of Adiponectin in the metabolic syndrome: Current perspectives on its modulation as a treatment strategyCurrent Pharmaceutical Design.  19:5755-5763. 2013
    2012 3D Cell Cultures. Mimicking In Vivo Tissues for Improved Predictability in Drug DiscoveryAnnual Reports in Medicinal Chemistry.  47:367-378. 2012
    2012 Process development and optimization for production of a potassium ion channel blocker, ICA-17043Organic Process Research and Development.  16:1385-1392. 2012
    2012 Frizzled7 as an emerging target for cancer therapyCellular Signalling.  24:846-851. 2012
    2012 The wnt/β-catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancerJournal of Cellular Biochemistry.  113:13-18. 2012
    2011 N -pyridyl and pyrimidine benzamides as KCNQ2/Q3 potassium channel openers for the treatment of epilepsyACS Medicinal Chemistry Letters.  2:481-484. 2011
    2004 Design of a gene family screening library targeting G-protein coupled receptorsJournal of molecular graphics.  23:15-21. 2004
    2004 Neuronal nicotinic acetylcholineExpert Opinion on Therapeutic Targets.  8:61-64. 2004
    2003 The design and synthesis of novel orally active inhibitors of AP-1 and NF-κB mediated transcriptional activation. SAR of in vitro and in vivo studiesBioorganic and Medicinal Chemistry Letters.  13:4077-4080. 2003
    2000 Inhibitors of NF-κB and AP-1 gene expression: SAR studies on the pyrimidine portion of 2-chloro-4-trifluoromethylpyrimidine-5-[N-(3',5'-bis(trifluoromethyl)-phenyl) carboxamide]Journal of Medicinal Chemistry.  43:3995-4004. 2000
    2000 Novel inhibitors of AP-1 and NF-κB mediated gene expression: Structure-activity relationship studies of ethyl 4-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-2-(trifluoromethyl)pyrimidine-5-carb oxylateBioorganic and Medicinal Chemistry Letters.  10:1645-1648. 2000
    2000 Designing chiral libraries for drug discoveryDrug Discovery Today.  5:364-372. 2000
    2000 Synthesis and structure-activity relationship studies of conformationally restricted, analogs of 2-chloro-4-trifluoromethylpyrimidine- 5-[N-(3',5'-bis(trifluoromethyl)phenyl)]carboxamideMedicinal Chemistry Research.  10:19-29. 2000
    1999 Developments in solution-phase combinatorial chemistryCurrent Opinion in Drug Discovery and Development.  2:377-384. 1999
    1998 A novel and T cell specific dual inhibitor of NF-κB and AP-1 suppresses alloreactivity in mice through its antiproliferative effect mediated by inhibition of IL-2 productionFederation proceedings.  12. 1998
    1998 2-Chloro-4-(trifluoromethyl)pyrimidine-5-N-(3',5'- bis(trifluoromethyl)phenyl)carboxamide: A potent inhibitor of NF-κB- and AP- 1-mediated gene expression identified using solution-phase combinatorial chemistryJournal of Medicinal Chemistry.  41:413-419. 1998
    1998 A general and regiospecific synthesis of 5,8-disubstituted α- tetralonesSynthetic Communications.  28:3491-3502. 1998
    1997 Novel approaches for the treatment of inflammatory diseases: Inhibitors of NF-κB and AP-1Current Pharmaceutical Design.  3:515-528. 1997
    1997 A novel inhibitor of nuclear factor-κB and activator protein-1 transcription factors in T cells suppresses host-versus-graft alloreactivity in vivoTransplantation Proceedings.  29:1269-1270. 1997
    1997 Ion-exchange resins for solution phase parallel synthesis of chemical librariesTetrahedron Letters.  38:513-516. 1997
    1997 Traceless linker: Oxidative activation and displacement of a sulfur-based linkerTetrahedron Letters.  38:211-214. 1997
    1996 SP100030 is a novel T-cell-specific transcription factor inhibitor that possesses immunosuppressive activity in vivoTransplantation Proceedings.  28:3106-3109. 1996
    1996 Peptide inhibitors of IκB protease: Modification of the C-termini of Z-LLF-CHOBioorganic and Medicinal Chemistry Letters.  6:2925-2930. 1996
    1996 Use of pentafluorophenyl esters for one-pot protection/activation of amino and thiol carboxylic acidsTetrahedron Letters.  37:4915-4918. 1996
    1995 Synthesis of Boxazomycin B and related analogsTetrahedron Letters.  36:7213-7216. 1995
    1994 Synthesis and Antibacterial Activity of New Quinolones Containing a 7-[3-(1-Amino-1-Methylethyl)-1-pyrrolidinyl] Moiety. Gram-Positive Agents with Excellent Oral Activity and Low Side-Effect PotentialJournal of Medicinal Chemistry.  37:733-738. 1994
    1994 An efficient method for the synthesis of (R)-3-(1-amino-1-methylethyl)pyrrolidines for the antiinfective agent, PD 138312Tetrahedron: Asymmetry.  5:1131-1134. 1994
    1993 Stereoselective Michael additions of nitromethane yielding 3R(1S N-substituted aminoethyl)pyrrolidinesTetrahedron Letters.  34:7529-7532. 1993
    1993 3-Ethenyl, 3-ethynyl, 3-aryl, and 3-cyclopropyl-2,4,6-trifluorobenzoic acids: Useful intermediate in the synthesis of quinolone antibacterialsTetrahedron Letters.  34:281-284. 1993
    1993 High capacity in vitro micronucleus assay for assessment of chromosome damage: results with quinolone / naphthyridone antibacterialsMutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental or Occupational Exposure.  298:227-236. 1993
    1993 Quinolone Antibacterials Containing the New 7-[3-(1-Aminoethyl)-1-pyrrolidinyl] Side Chain: The Effects of the 1-Aminoethyl Moiety and Its Stereochemical Configurations on Potency and in Vivo EfficacyJournal of Medicinal Chemistry.  36:871-882. 1993
    1992 Development of radioimmunoassays for measurement of the specific bronchodilator procaterol in human urine and plasmaJournal of Clinical Immunoassay.  15:258-264. 1992
    1992 Fluoroquinolones: Relationships between Structural Variations, Mammalian Cell Cytotoxicity, and Antimicrobial ActivityJournal of Medicinal Chemistry.  35:4745-4750. 1992
    1992 Synthesis of chiral 3-substituted-3-aminomethyl-pyrrolidines and related compoundsMathematical Problems in Engineering.  29:1441-1448. 1992
    1992 The biochemistry and pharmacology of PD 116124 (8-amino-2'- nordeoxyguanosine), an inhibitor of purine nucleoside phosphorylase (PNP)Journal of Pharmacology and Experimental Therapeutics.  260:319-326. 1992
    1992 Antibacterial Agents, Targets and ApproachesAnnual Reports in Medicinal Chemistry.  27:119-128. 1992
    1992 Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908)International Journal of Radiation Oncology - Biology - Physics.  22:545-548. 1992
    1992 Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agentsInternational Journal of Radiation Oncology - Biology - Physics.  22:549-551. 1992
    1992 Synthesis of chiral 3‐substituted‐3‐aminomethyl‐pyrrolidines and related compoundsJournal of Heterocyclic Chemistry.  29:1441-1448. 1992
    1991 Synthesis and Evaluation of a Series of 3,5-Disubstituted Benzisoxazole-4,7-diones. Potent Radiosensitizers in VitroJournal of Medicinal Chemistry.  34:3290-3294. 1991
    1991 A New Class of Analogues of the Bifunctional Radiosensitizer α-(1-Aziridinylmethyl)-2-nitro-1ff-imidazole-1-ethanol (RSU 1069): The CycloalkylaziridinesJournal of Medicinal Chemistry.  34:2484-2488. 1991
    1991 Dihydroisoquinolinones: The design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymeraseAnticancer Drug Design.  6:107-117. 1991
    1991 Dual-Function Radiosensitizers. α-[[(2-Bromoethyl)amino]methyl]-2-nitro-1H-imidazole-1-ethanol and Related Compounds: Preparation via an Aziridine EquivalentJournal of Medicinal Chemistry.  34:1207-1209. 1991
    1991 Chapter 16. RadiosensitizersAnnual Reports in Medicinal Chemistry.  26:151-160. 1991
    1991 Effects of PD 128763, a new potent inhibitor of poly(ADP-ribose) polymerase, on X-ray-induced cellular recovery processes in Chinese hamster V79 cellsRadiation Research.  126:367-371. 1991
    1991 Inhibitors of poly(ADP-ribose) polymerase (ADPRP): Potential chemotherapeutic agentsDrugs of the future.  16:723-739. 1991
    1990 Synthesis and Evaluation of α-[[(2-Haloethyl)amino]methyl]-2-nitro-1H-imidazole-l-ethanols as Prodrugs of α-[(l-Aziridinyl)methyl]-2-nitro-1H-imidazole-1-ethanol (RSU-1069) and its Analogues Which Are Radiosensitizers and Bioreductively Activated CytotoxinsJournal of Medicinal Chemistry.  33:2603-2610. 1990
    1988 1,4-Dihydropyridine Antagonist Activities at the Calcium Channel: A Quantitative Structure-Activity Relationship ApproachJournal of Medicinal Chemistry.  31:2103-2107. 1988
    1987 8-amino-9-substituted guanines: Potent purine nucleoside phosphorylase (PNP) inhibitorsAgents and actions.  21:253-256. 1987
    1987 Approaches to the Synthesis of Ring C Transposed Progesterone Analogues. rac -7β,15α-Ethano-11,12-seco-11,19-bisnor-17α-pregn-4-ene-3,20-dione and rac-4,4-Dimethyl-7,7-(ethylenedioxy)-(4aα,4bβ,8aα, 10aβ)-perhydro-3-phenanthrenoneJournal of Organic Chemistry.  52:2263-2273. 1987
    1986 Inhibitors of Human Purine Nucleoside Phosphorylase. Synthesis, Purine Nucleoside Phosphorylase Inhibition, and T-Cell Cytotoxicity of 2,5-Diaminothiazolo[5,4-d]pyrimidin-7(6H)-one and 2,5-Diaminothiazolo[4,5-d]pyrimidin-7(6H)-one. Two Thio Isosteres of 8-AminoguanineJournal of Medicinal Chemistry.  29:1804-1806. 1986
    1982 Relative Affinity of 17α- and/or 21-Esters and 17α,21-Diesters of Cortisol for a Glucocorticoid Receptor from Rat ThymocytesJournal of Medicinal Chemistry.  25:747-749. 1982
    1980 Effect Of C-21 Substituents on the Elimination of a 17α-Acyloxy Group from 17α-(Acyloxy)-20-Oxo SteroidsJournal of Organic Chemistry.  45:2012-2013. 1980


    Year Title Altmetric
    2006 Antiarrhythmic Agents.  Ed. 41.  2006

    Research Overview

  • Keywords - New Therapies for Cancer, Infectious Diseases, and Neurological Diseases and Disorders
  • Education And Training

  • Doctor of Philosophy in Medicinal/Pharmaceutical Chemistry, State University of New York System : Buffalo 1982
  • Full Name

  • Mark Suto